Linking YAP to Müller Glia Quiescence Exit in the Degenerative Retina

Annaïg Hamon, Diana García-García, Divya Ail, Juliette Bitard, Albert Chesneau, Deniz Dalkara, Morgane Locker, Jérôme E. Roger, Muriel Perron

To cite this version:


HAL Id: hal-02136721
https://hal.sorbonne-universite.fr/hal-02136721
Submitted on 22 May 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Linking YAP to Müller Glia Quiescence Exit in the Degenerative Retina

Graphical Abstract

Highlights

- YAP is required for 
  Xenopus Müller glia proliferation in response to injury
- YAP is required for mouse Müller glia exit from quiescence upon degeneration
- YAP5SA reprograms mouse Müller glia into highly proliferative cells
- YAP functionally interacts with EGFR signaling in Müller cells

Authors

Annaïg Hamon, Diana García-García, Divya Ail, ..., Morgane Locker, Jérôme E. Roger, Muriel Perron

Correspondence

jerome.roger@u-psud.fr (J.E.R.), muriel.perron@u-psud.fr (M.P.)

In Brief

While fish and amphibian Müller cells behave as retinal stem cells upon injury, their regenerative potential is limited in mammals. Hamon et al. show that YAP is required for their cell-cycle re-entry in 
Xenopus and is sufficient in mouse to awake them from quiescence and trigger their proliferative response.
Linking YAP to Müller Glia Quiescence Exit in the Degenerative Retina

Annaïg Hamon,1,3 Diana García-García,1,3 Divya Ail,1,3 Juliette Bitard,3 Albert Chesneau,1 Deniz Dalkara,2 Morgane Locker,1 Jérôme E. Roger,1,4 and Muriel Perron1,4

1Paris-Saclay Institute of Neuroscience, CERTO-Retina France, CNRS, Univ Paris Sud, Université Paris-Saclay, Orsay 91405, France
2Sorbonne Université, UPMC Univ Paris 06, INSERM, CNRS, Institut de la Vision, Paris, France
3These authors contributed equally
4Lead Contact
*Correspondence: jerome.roger@u-psud.fr (J.E.R.), muriel.perron@u-psud.fr (M.P.)

SUMMARY

Contrasting with fish or amphibian, retinal regeneration from Müller glia is largely limited in mammals. In our quest toward the identification of molecular cues that may boost their stemness potential, we investigated the involvement of the Hippo pathway effector YAP (Yes-associated protein), which is upregulated in Müller cells following retinal injury. Conditional YAP deletion in mouse Müller cells prevents cell-cycle gene upregulation that normally accompanies reactive gliosis upon photoreceptor cell death. We further show that, in Xenopus, a species endowed with efficient regenerative capacity, YAP is required for their injury-dependent proliferative response. In the mouse retina, where Müller cells do not spontaneously proliferate, YAP overactivation is sufficient to induce their reprogramming into highly proliferative cells. Overall, we unravel a pivotal role for YAP in tuning Müller cell proliferative response to injury and highlight a YAP-EGFR (epidermal growth factor receptor) axis by which Müller cells exit their quiescence state, a critical step toward regeneration.

INTRODUCTION

Neurodegenerative retinal diseases, such as retinitis pigmentosa or age-related macular degeneration, ultimately lead to vision loss, as a consequence of photoreceptor cell death. Driving retinal self-repair from endogenous neural stem cells in patients represents an attractive therapeutic strategy. Among cellular sources of interest are Müller cells, the major glial cell type in the retina (Bringmann et al., 2006). In certain species, such as zebrafish or Xenopus, they behave as genuine stem cells, endowed with the ability to reprogram into a progenitor-like state upon retinal damage, proliferate, and regenerate lost photoreceptors (Hamon et al., 2016; Langhe et al., 2017; Wan and Goldman, 2016). In mammals, however, their proliferative response to injury is extremely limited. Following acute retinal damage, mouse Müller glial cells rapidly re-enter the G1 phase of the cell cycle, as inferred by increased cyclin gene expression, but they rarely divide (Dyer and Cepko, 2000). Suggesting that they nonetheless retain remnants of repair capacities, their proliferation and neurogenic potential can be stimulated, by supplying exogenous growth factors such as heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF), by overexpressing the proneural gene Ascl1a, or via cell fusion with Wnt-activated transplanted stem cells (Hamon et al., 2016; Jorstad et al., 2017; Sanges et al., 2016; Ueki et al., 2015; Wilken and Reh, 2016). Our understanding of the genetic and signaling network sustaining Müller cell stemness potential is, however, far from being complete. Identifying novel molecular cues is thus of utmost importance to foresee putative candidates that could be targeted for regenerative medicine. We here investigated whether the Hippo pathway effector YAP might influence Müller cell reactivation and how it would intersect with other critical signaling pathways.

The Hippo pathway is a kinase cascade that converges toward two terminal effectors, YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif). Both are transcriptional coactivators of TEAD family transcription factors. The Hippo pathway emerged as a key signaling in a wide range of biological processes (Fu et al., 2017), including stem cell biology (Barry and Camargo, 2013; Mo et al., 2014). Of note, it proved to be dispensable under physiological conditions in some adult stem cells, such as mammary gland, pancreatic, intestinal, and importantly, neural stem cells (Azzolin et al., 2014; Chen et al., 2014a; Huang et al., 2016; Zhang et al., 2014). It can nonetheless become essential under pathological conditions, as described, for example, in the context of intestinal regeneration following injury (Barry et al., 2013; Gregoireff et al., 2015). YAP status in adult neural tissue repair has hitherto never been investigated. We recently discovered that YAP and TEAD1 are specifically expressed in murine Müller cells, and that their expression and activity are enhanced upon retinal damage (Hamon et al., 2017). We thus sought to determine whether YAP could be required for injury-induced Müller glia reactivation. We found in mouse that YAP triggers cell-cycle gene upregulation in Müller glial cells following photoreceptor cell death. In line with the idea of a conserved role in Müller cell-cycle re-entry, blocking YAP function in Xenopus results in a dramatically reduced proliferative response following acute retinal damage or photoreceptor cell ablation. Finally, we report that the limited proliferative response of murine Müller glia can be circumvented...
and significantly enhanced by YAP overexpression. We further show such YAP mitogenic function relies on its interplay with epidermal growth factor receptor (EGFR) signaling. As a whole, this study highlights the critical role of YAP in driving Müller cells to exit quiescence and thus reveals a potential target for regenerative medicine.

RESULTS

Yap Conditional Knockout in Mouse Müller Cells Does Not Compromise Their Maintenance under Physiological Conditions

To investigate the role of YAP in murine Müller glias, we generated a Yap^flox/flox; Rax-CreER<sup>T2</sup> mouse line allowing for Cre-mediated conditional gene ablation specifically in Müller cells (Pak et al., 2014; Reginensi et al., 2013). It is thereafter named Yap CKO (conditional knockout), whereas “control” refers to Yap<sup>flox/flox</sup> mice. Yap deletion was induced in fully differentiated Müller cells, through 4-hydroxytamoxifen (4-OHT) intraperitoneal injection at postnatal day (P) 10 (Figure 1A). Phenotypic analyses were then conducted on 2-month-old mice. We first confirmed Müller cell-specific Cre expression and Yap deletion efficiency in Yap CKO mice carrying the Rosa26-CAG-lox-stop-lox-TdTomato reporter (Ai9) transgene (Figures 1B and 1C). We next wondered whether expression of TAZ (the second effector of the Hippo pathway) could be increased in our model and thus potentially compensate for Yap deletion, as previously reported in mammalian cell lines (Finch-Edmondson et al., 2015). In these physiological conditions, TAZ protein level was actually similar in Yap CKO and control mice (Figure S1A), suggesting an absence of compensatory mechanisms. Finally, we assessed global retinal organization and function in Yap CKO mice. Immunostaining for various retinal neuron markers and electroretinogram (ERG) recordings under scotopic and photopic conditions revealed neither structural nor functional difference compared with control retinas (Figures S1B–S1D). Müller cells, whose identity was assessed with Sox9 labeling, were also normally distributed (Figure 1D). They did not display any sign of stress

![Figure 1. Yap CKO Retinas Exhibit Altered Transcriptional Response to Injury](image-url)

(A) Timeline diagram of the experimental procedure used in (B–E). Yap<sup>flox/flox</sup> mice with or without the Ai9 reporter allele (control or control;Ai9) and Yap<sup>flox/flox;Rax-CreER<sup>T2</sup></sup> mice with or without the Ai9 reporter allele (Yap CKO or Yap CKO;Ai9) received a single dose of 4-OHT at P10 and were analyzed at P60. (B) Retinal sections immunostained for TdTomato, glutamine synthetase (GS; a Müller cell marker), or YAP. (C) Western blot analysis of YAP expression on retinal extracts. α-Tubulin labeling was used to normalize the signal. n = 4 mice for each condition. (D) Retinal sections immunostained for SOX9. n = 3 mice for each condition. (E) Retinal sections immunostained for GFAP or Vimentin. (F) Timeline diagram of the experimental procedure used in (G) and (H). Yap<sup>flox/flox</sup> (control) and Yap<sup>flox/flox;Rax-CreER<sup>T2</sup></sup> (Yap CKO) mice received a single dose of 4-OHT at P10 and a single dose of MNU at 2 months. Retinas were then subjected to RNA-sequencing 16 h later. (G) Pie chart representing the number of DEGs found to be upregulated or downregulated in MNU-injected Yap CKO retinas compared with MNU-injected control ones. (H) Results of Gene Ontology (GO) enrichment analysis exemplifying six over-represented GO biological processes related to retinal response to injury. In (B), (D), and (E), nuclei were counterstained with DAPI (blue). Mann-Whitney test, *p < 0.05. All results are reported as mean ± SEM. Scale bars, 20 μm. GCL, ganglion cell layer; INL, inner nuclear layer; ns, non-significant; ONL, outer nuclear layer. See also Figures S1 and S2 and Table S1.
reactivity, as inferred by the expression of intermediate filament proteins, glial fibrillary acidic protein (GFAP), and Vimentin (Figure 1E). Taken together, these results demonstrate that lack of YAP expression in Müller cells from P10 does not impact the overall retinal structure, neuron and glia maintenance, nor the visual function in 2-month-old mice.

**Yap Deletion Impairs Mouse Müller Cell Reactivation upon Photoreceptor Degeneration**

We next investigated YAP function in a degenerative context. Retinal degeneration was triggered in Yap CKO mice through in vivo methylnitrosourea (MNU) injections, a well-established paradigm for inducible photoreceptor cell death (Chen et al., 2014b). In order to evaluate the impact of Yap deletion on Müller glia early response to injury, all of the analyses were performed 16 h after MNU injection, at the onset of photoreceptor cell death (Figures 1F and S2A). As previously described (Hamon et al., 2017), YAP protein expression level was upregulated in wild-type (WT) retinas upon MNU injection, and as expected, we found it effectively decreased in our MNU-injected Yap CKO model (Figure S2B). In contrast with the physiological situation, this was accompanied by a compensatory increase of TAZ levels (Figure S2C). Yet, this enhanced expression is likely insufficient to entirely compensate for the loss of YAP activity, as inferred by the downregulation of Cyr61, a well-known YAP/TAZ target gene (Lai et al., 2011; Figure S2D). We next assessed GFAP expression as a marker of reactive gliosis upon MNU injection. Interestingly, we found it increased at both the mRNA and protein levels in Yap CKO mice compared with control ones, reflecting a potential higher degree of retinal stress (Figures S2E and S2F). This led us to further investigate the molecular impact of Yap deletion in reactive Müller cells, through a large-scale transcriptomic analysis comparing non-injected WT mice, MNU-injected control mice, and MNU-injected Yap CKO mice. This allowed identifying 305 differentially expressed genes (DEGs), 75% of them being downregulated in MNU-injected Yap CKO retinas compared with MNU-injected control ones (Figure 1G; Table S1). The top-enriched biological processes they belong to include “response to chemical,” “regulation of cell proliferation,” and “inflammatory response.” This strongly suggests that lack of YAP expression profoundly alters Müller cell transcriptional response to retinal injury (Figure 1H).

**Yap Knockout Prevents Cell-Cycle Gene Upregulation in Mouse Reactive Müller Cells**

As we were seeking for a potential function of YAP in Müller cell reactivation, we focused our interest on identified genes related to the GO group “regulation of cell proliferation.” Z score-based hierarchical clustering for the 70 corresponding DEGs revealed three distinct clusters (Figure S3A). One particularly caught our attention because the 52 DEGs it contains appear less responsive to injury in the absence of YAP. These are indeed: (1) expressed at very low levels in wild-type mice, (2) strongly upregulated in MNU-injected control mice, (3) while being only moderately enriched in MNU-injected Yap CKO mice. This is the case, for instance, of four cell-cycle regulator coding genes, Ccnd1, Ccnd2, Ccnd3, and Cdk6 (Figure 2A). Further validation was conducted by qPCR, immunostaining, and western blot for Cyclin D1 and Cyclin D3, which are specifically expressed in Müller cells. This confirmed their downregulation upon MNU injection in Yap CKO mice compared with controls (Figures 2B–2D). Noticeably, we found that the pluripotent leukemia inhibitory factor (LIF) and the reprogramming factor Klf4 follow the same profile, suggesting that the reprogramming process that initiates along with Müller cell-reactive gliosis is also impaired by Yap loss of function (Figure S3B).

To strengthen our results in a model closer to human retinal disease, we generated Yap CKO;rd10 mice by breeding the Yap CKO line into the rd10 background (Pde6bd10 line, a model of retinitis pigmentosa) (Chang et al., 2007; McLaughlin et al., 1995). We next assayed Cyclin D1 and Cyclin D3 expression at P20 (Figures S4A and S4B), which corresponds to the period of intense rod cell death in rd10 mice (Chang et al., 2007). As observed with the MNU model, protein levels for both cyclins were increased in Müller cells upon photoreceptor degeneration, and this upregulation was impaired in Yap CKO retinas. Taken together, these results demonstrate YAP involvement in the injury-induced transcriptional activation of cell-cycle genes, which likely reflects its role in pushing Müller cells out of their quiescent state. Of note, a YAP-dependent control of Cyclin D1 and D3 expression was also observed in physiological conditions (Figures S4C and S4D), suggesting that YAP regulates the basal level of cell-cycle genes in quiescent Müller cells as well.

**Inhibition of YAP Prevents Müller Glia Proliferation upon Acute Retinal Damage or Selective Photoreceptor Cell Ablation in Xenopus laevis**

All of the above results converge to the idea that YAP triggers cell-cycle re-entry of quiescent Müller glia upon injury. Because this process is not complete in murine Müller cells (they reactivate G1 phase genes but rarely divide), we turned to the frog to strengthen our hypothesis. Xenopus is an animal model endowed with regenerative capacity, in which Müller cells efficiently respond to injury by intense proliferation (Langhe et al., 2017). We first confirmed that, within the Xenopus central neural retina, YAP expression is restricted to Müller cells (Figure 3A) (Cabochette et al., 2015), as observed in mouse. We next sought to assess the impact of YAP inhibition by taking advantage of a Xenopus laevis transgenic line, hereafter named Tg(dnYAP), in which a heat shock promoter (Hsp70) drives the expression of a dominant-negative YAP variant (Hayashi et al., 2014a; Nishioka et al., 2009; Figures 3B, S5A, and S5B). We first verified that heat-shocked Tg(dnYAP) embryos displayed a small eye phenotype, as previously demonstrated following Yap-Morpholino injection (Cabochette et al., 2015). Moreover, we found that this defective eye growth could be rescued by overexpressing an inducible and constitutively active form of YAP, YAPS98A-GR (Figures S5C–S5E). At latter developmental stages, two YAP target genes, Ctgf (connective tissue growth factor) and Cyr61, were downregulated in Tg(dnYAP) tadpole retinas upon heat-shock induction (Figure S5F). Altogether, these results validated the efficacy and specificity of dnYAP in inhibiting endogenous YAP function. We next assayed Müller cell proliferative response in a model of stab injury (Figure 3C). Importantly, we previously demonstrated that a majority of proliferating cells found at the injury site are indeed Müller cells
Comparison of 5-bromo-2′-deoxyuridine (BrdU) incorporation in heat-shocked and non-heat-shocked wild-type retinas confirmed that heat shock does not affect proliferation by itself (Figure 3D). In contrast, the number of BrdU-labeled cells at the injury site was reduced by about 60% in heat-shocked Tg(dnYAP) tadpole retinas compared with controls (non-heat-shocked transgenic animals or heat-shocked non-transgenic siblings; Figure 3D). Of note, loss of YAP activity did not affect Müller cell density (Figure S5G), ruling out the possibility that defective BrdU incorporation might be due to an impaired cell survival. Finally, YAP requirement for Müller glia proliferative response to stab injury could be confirmed at post-metamorphic stage in froglets, with Tg(dnYAP) retinas exhibiting a reduction of 80% of BrdU-positive cells compared with controls (Figures 3E and 3F).

We next sought to reinforce these data in a model closer to the mouse MNU or rd10 paradigms. In this purpose, we turned to a Xenopus laevis transgenic line that we previously established, allowing for conditional selective rod cell ablation (Langhe et al., 2017) [Tg(Rho:GFP-NTR), hereafter named Tg(NTR)] (Figure 4A). This transgenic line expresses the nitroreductase (NTR) gene under the control of the Rhodopsin promoter, and photoreceptor degeneration can be induced by adding the enzyme ligand metronidazole (MTZ) to the tadpole rearing medium. Here again, we previously showed that about 80% of cells that proliferate upon rod cell ablation are indeed Müller cells (Langhe et al., 2017). The Tg(dnYAP) and Tg(NTR) lines were crossed to generate double-transgenic animals, in which inhibition of YAP can be triggered by heat shock, and photoreceptor degeneration can be induced by adding the enzyme ligand metronidazole (MTZ) to the tadpole rearing medium. Here again, we previously showed that about 80% of cells that proliferate upon rod cell ablation are indeed Müller cells (Langhe et al., 2017). The Tg(dnYAP) and Tg(NTR) lines were crossed to generate double-transgenic animals, in which inhibition of YAP can be triggered by heat shock, and photoreceptor degeneration can be induced by adding the enzyme ligand metronidazole (MTZ) to the tadpole rearing medium. Here again, we previously showed that about 80% of cells that proliferate upon rod cell ablation are indeed Müller cells (Langhe et al., 2017).

Based on the above data on Xenopus, we next wondered whether mouse Müller cell inability to proliferate upon injury (despite cell-cycle gene reactivation) might be linked to insufficient levels of YAP expression. For this purpose, we generated a knockin model in which YAP is forcedly expressed in Müller glial cells, generating a constitutive overexpression of YAP that is independent of any injury (Figure 5A). We found that forced YAP expression could partially rescue proliferation in response to both rod cell ablation and stab injury (Figure 5B). Importantly, these data were accompanied by a significant increase in YAP expression levels in Müller glial cells (Figure 5C). Altogether, these data strongly support the idea that in different lesional contexts, YAP is required for Müller glia cell-cycle re-entry and proliferation.
of YAP activity. To investigate this hypothesis, we decided to overexpress in mouse Müller cells a FLAG-tagged mutated YAP protein, YAPSSA, which is insensitive to Hippo pathway-mediated cytoplasmic retention (Zhao et al., 2007). To deliver this constitutively active form of YAP, we took advantage of an adeno-associated virus (AAV) variant, ShH10, which selectively targets Müller cells (Klimczak et al., 2009; Figures 5A and S6A–S6C). We then started by infecting retinal explants, a spontaneous model of retinal degeneration (Müller et al., 2017). We first found that levels of Cyclin D1 were significantly increased upon AAV-YAP5SA transduction compared with that of AAV-GFP-infected controls (Figures 5B and 5C). We next analyzed Müller cell proliferative activity through an EdU incorporation assay. In explants overexpressing YAPSSA, EdU labeling was strongly enhanced, with numerous patches containing a high density of EdU-positive cells (Figure 5D) found in regions with the highest infected cell density (as assessed by FLAG immunostaining; data not shown). Further quantitative analyses within the explant inner nuclear layer revealed that after a 7-day culture: (1) about 50% of YAP5SA-expressing cells were EdU labeled (Figures S6D and S6E), (2) the great majority (more than 88%) of EdU-positive cells were Müller cells (as inferred by their Sox9 labeling and their position; Figures S6F and S6G), and (3) up to ~25% of Müller cells were proliferating in AAV-YAPSSA-infected explants (Figure 5E). Of note, after such a 7-day culture, EdU-positive cells were mainly found in the explant periphery, where neurons are presumably more prone to degenerate (more exposed than those in the center). Importantly, however, after longer culture time period (12 days instead of 7), proliferation spread into the whole infected explant, and the percentage of EdU-labeled Müller cells then reached more than 75% (Figure 5F).

We next assessed the mitogenic potential of YAPSSA in vivo, following intravitreal AAV injection in adult mice (Figures 5G and 5H). Only rare proliferative cells were observed in control retinas. In contrast, many EdU-positive cells were found in retinas transduced with AAV-YAPSSA. Co-labeling with glutamine synthetase or SOX9 on retinal sections confirmed that a majority of these had a Müller cell identity (Figure S7A and data not shown). YAPSSA can thus trigger Müller glia cell-cycle re-entry in vivo. Altogether, these data reveal that YAP overactivation is sufficient to override the dormancy of murine Müller glial cells and boost their proliferative potential. Additionally, as shown in Figures S7B and S7C, increased expression of Ascl1 was observed
in AAV-YAP5SSA-infected retinas. This is reminiscent of the zebrafish situation, where such upregulation occurs in dedifferentiating Müller cells in response to retinal injury (Ramachandran et al., 2010).

**Interfering with Yap Expression Affects EGFR Signaling in Mouse Reactive Müller Cells**

We then sought to identify the molecular mechanisms underlying Yap effect on Müller glia cell-cycle re-entry. Besides cell-cycle genes, our RNA-sequencing (RNA-seq) dataset and pathway analysis also revealed a deregulation of several members of the EGFR pathway in the Yap CKO degenerative background (Figures S3A and S3C). Importantly, EGFR signaling is well known for its mitogenic effects on Müller cells during retinal degeneration. Two EGFR ligands, namely EGF or HB-EGF, have in particular been shown to stimulate Müller glia proliferation in zebrafish, chick, or rodents (Close et al., 2006; Karl et al., 2008; Todd et al., 2015; Wan et al., 2012, 2014).

As observed with cell-cycle genes, both Egfr and two ligand-coding genes (Hbegf and Neuregulin 1) failed to be properly upregulated upon MNU injection in Yap CKO retinas compared with control ones (Figure 6A). Expression of another EGFR-coding gene, Erbb4 (named also Her4), did not appear sensitive to MNU injection in control retinas but was still found significantly decreased in MNU-injected Yap CKO mice (Figure 6A).

In order to decipher whether these deregulations might be associated with defective EGFR signaling activity, we next assessed the status of the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K)/AKT (also known as protein kinase B) pathways, which are known to be required for Müller cell proliferative response to growth factor treatment upon injury (Beach et al., 2017; Ueki and Reh, 2013; Wang et al., 2016). Western blot analysis revealed activation of the extracellular signal-related kinase (ERK) and AKT signaling pathways following MNU injection in control retinas. In the Yap CKO context, this increase was significantly attenuated, reflecting lower signaling activation (Figure 6B). Importantly, phosphorylated-ERK (P-ERK) immunostaining confirmed that this decrease was indeed happening in Müller cells: P-ERK labeling (which is barely detectable in non-injured retinas; data not shown) was localized in Müller cell nuclei and processes upon MNU injection and exhibited differential enhancement in control mice (strong signal) compared with Yap CKO ones (weaker signal; Figure 6C). Together, these results suggest that Yap is required for proper EGFR signaling through its transcriptional control on both EGFR ligands and receptors. In line with this idea, we found that YAP5SSA was sufficient to upregulate Egfr expression upon AAV intraocular injections (Figures 6D and 6E). Hbegf levels showed a slight trend upward in retinas infected with AAV-YAP5SSA, but this did not reach the level of statistical significance. This further supports the idea that Yap regulates the EGFR pathway in Müller glia.

**YAP Mitogenic Effects on Müller Cells Requires EGFR Pathway Activity**

In order to investigate whether this YAP-EGFR interaction might converge on cell-cycle gene regulation, we attempted to rescue the Yap CKO phenotype through EGFR signaling activation. To this aim, we first decided to treat Yap CKO explants with HB-EGF, because this EGFR ligand failed to be properly upregulated upon MNU treatment in the absence of YAP and, in contrast, was found increased upon infection with AAV-YAP5SSA (Figures 6A and 6E). As expected from our previous observations in MNU and rd10 mice (Hamon et al., 2017), we found an increase in Yap level accompanying the degenerative process in explants (Figures 7A and 7B). Moreover, as described above with both paradigms (Figures 2D and S4B), this correlated with Cyclin D1 upregulation (Figures 7C and 7D, compare lanes 1 and 2), and this response was impaired in Yap CKO explants (Figure 7D,
compare lanes 2 and 3). Following HB-EGF addition, Cyclin D1 levels were indistinguishable between Yap CKO and control explants (Figure 7D, compare lanes 4 and 5). We next attempted an in vivo rescue following intravitreal injection of HB-EGF in Yap CKO/rd10 mice. We found that expression of both Cyclin D1 and Cyclin D3 could be restored to the untreated control level (Figures 7E and 7F, compare lanes 2 and 5). Finally, to strengthen the idea of YAP acting upstream the EGFR pathway in Müller glia cell-cycle gene regulation, we assessed whether blocking the EGFR pathway could impair YAPSSA mitogenic effects on Müller glia. We found indeed that pharmacological inhibition of Erk phosphorylation using explant treatment with U0126 (Figures 7G and 7H) dramatically decreased YAPSSA-dependent EdU incorporation in Müller cells (Figure 7I). By demonstrating the EGFR signaling requirement downstream of YAP activity, this result strongly supports a model whereby in vivo functional interaction between the two pathways promotes Müller cell proliferative response.

**DISCUSSION**

Through back-and-forth investigations in both mouse and *Xenopus* retinas, we discovered a pivotal role for YAP in the regulation of Müller cell response to injury. We in particular reveal that YAP triggers their exit from quiescence in a degenerative context. In *Xenopus*, this is accompanied with intense proliferation, but not in mouse. We, however, demonstrate that enhancing YAP activity is sufficient to boost the naturally limited proliferative potential of mammalian Müller glia. In addition, our findings unravel a YAP-EGFR axis in Müller glia cell-cycle re-entry that sheds a new light on the genetic network underlying their recruitment following retinal injury.

YAP knockout in several mammalian organs, such as liver, pancreas, intestine, and mammary gland, unexpectedly suggested that this factor is dispensable to maintain normal adult tissue homeostasis (Piccolo et al., 2014). In line with this, we did not observe any major abnormalities in Yap CKO retinal morphology and function. We, however, revealed YAP requirement in reactive Müller glia. Reactive gliosis occurs upon retinal stress or injury (Bringmann et al., 2009) and includes a series of characteristic morphological and molecular changes. Importantly, a feature of reactive Müller cells is their exit from a quiescent G0 state. Although their cell cycle rarely reaches S phase, G0 to G1 progression is in particular materialized by the upregulation of genes encoding components of Cyclin D-Cdk-dependent kinase (CDK) complexes, known to drive early to mid-G1 phase progression (Suga et al., 2014). We found that many cell-cycle genes, including *Ccnd* and *Cdk* genes, are downregulated in Yap CKO reactive Müller cells, suggesting that this process is impaired in the absence of YAP. Many different transcription factors have been identified that directly regulate *Ccnd1* promoter (Wang et al., 2004). Remarkably, YAP has been described as one of them in cancer cells (Mizuno et al., 2012). In addition, *Ccnd1* was shown to be activated by YAP overexpression in the chick neural tube (Cao et al., 2008). However, in that study, the authors reported that YAP is not required for its basal transcription. In contrast, we found in Müller cells that YAP is necessary both to maintain basal levels of Cyclin D1 in physiological conditions and for enhancing its expression upon injury. This reinforces the hypothesis that *Ccnd1* may be a direct YAP target gene in Müller glia. This could also be the case for *Cdk6*, as previously reported in a human fibroblastic cell line (Xie et al., 2013). Although our data suggest that YAP functions upstream of the EGFR pathway in the regulation of cell-cycle genes, we thus do not exclude EGFR-independent mechanisms as well.

Although dispensable in several homeostatic contexts, YAP is now well recognized as a central player in the regeneration of diverse tissues in different organisms (Barry and Camargo, 2013). As far as Xenopus is concerned, its importance in tissue repair had previously been demonstrated in the context of epimorphic limb and tail regeneration (Hayashi et al., 2014a, 2014b). We here bring new insights to the field by highlighting its requirement for *Xenopus* Müller cell proliferation in a lesioned or degenerative context. In mammals, YAP overexpression or Hippo pathway inhibition was already reported to stimulate regeneration of several injured organs, such as the heart, liver,
or intestine (Johnson and Halder, 2014; Loforese et al., 2017; Wang et al., 2018). Furthermore, it was recently discovered that YAP/TAZ can act as reprogramming factors, able to turn differentiated cells into their corresponding somatic stem cells.

**Figure 6. YAP Regulates the Expression of EGFR Signaling Components**

(A) Relative RNA expression (in fragments per kilobase of exon per million fragments mapped [FPKM]; data retrieved from the RNA-seq experiment) of *Egfr*, *Erbb4*, *Hbegf*, and *Neuregulin1* (*Nrg1*), in retinas from non-injected WT mice or control and Yap CKO mice injected with 4-OHT and MNU as shown in Figure 1F.

(B) Western blot analysis of P-ERK/ERK and P-AKT/AKT ratios on the same experimental conditions. α-Tubulin labeling was used to normalize the signal. n = 6 mice for each condition.

(C) Retinal sections from control and Yap CKO mice, immunostained for P-ERK. Nuclei are counterstained with DAPI (blue).

(D) Timeline diagram of the experimental procedure used in (E). WT mice were intravitreally injected with AAV-GFP (control) or AAV-YAP5SA. Retinas were then harvested 1 month later for qPCR analysis.

(E) qRT-PCR analysis of *Hbegf* and *Egfr* expression (10 biological replicates per condition). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.

Mann-Whitney test (except in A where p values were obtained using EdgeR). *p ≤ 0.05, **p ≤ 0.01; ***p ≤ 0.001. All results are reported as mean ± SEM. ns, non-significant. Scale bar: 20 μm. See also Figure S3.

(Monroe et al., 2019; Panciera et al., 2016). We here report that enhancing YAP activity awakens quiescent Müller cells and powerfully boosts their proliferative properties both ex vivo and in vivo. This might be accompanied by their dedifferentiation as inferred from the up-regulation of *Ascl1* expression. Investigating this issue will require assessing whether other retinal progenitor markers are re-expressed in these proliferating Müller cells in order to further characterize their identity. Whether the increased proliferation of YAP-overexpressing Müller cells leads to the production of new neuronal cells will also be an important point to address. Interestingly, following conditional overexpression of Yap555A, Rueda et al. (2019 [this issue of Cell Reports]) confirmed Müller glia cell-cycle re-entry and further showed that a very small subset of reactivated cells may indeed differentiate into neurons. Given YAP efficient mitogenic activity, getting higher rates of differentiation will presumably require (1) controlling its expression in a defined time period using genetic tools allowing for its transient activation (for instance, a doxycycline-inducible construct as previously described) (Panciera et al., 2016); and (2) overexpressing afterward transcription factors known to promote...
Figure 7. EGFR Signaling Is Required for YAP-Induced Proliferation of Müller Cells
(A) Timeline diagram of the experimental procedure used in (B). Retinas from WT mice were flattened and cultured for 0, 16, or 72 h.
(B) Western blot analysis of YAP expression on retinal explant extracts. α-Tubulin labeling was used to normalize the signal. n = 3 mice for each condition.

(legend continued on next page)
neuronal specification, as reported in a recent study describing Wnt-dependent retinal regeneration (Yao et al., 2018).

YAP is now well recognized as a molecular hub connecting several key signaling pathways (Barry and Camargo, 2013). In animal models harboring retinal regeneration properties such as zebrafish or chick (Hamon et al., 2016; Kaur et al., 2018; Wan and Goldman, 2016), several factors, like Notch, Wnt, or Shh, were shown to regulate Müller cell proliferative response. Given the known interplay between YAP and these pathways in various cellular contexts (Lin et al., 2012; Yu et al., 2015), it would be interesting to seek for their potential functional interactions in *Xenopus* Müller cell-dependent retinal regeneration. In mammals, Hippo/Wnt cross-talks are in particular well documented (Hansen et al., 2015), and Wnt is known to efficiently stimulate Müller cell proliferation following injury (Yao et al., 2018). However, our RNA-seq analysis did not highlight Wnt among the pathways that are deregulated upon Yap deletion. In contrast, we here revealed that YAP is required for proper expression and activity of EGFR pathway components in Müller cells following retinal degeneration. Such functional interaction was previously reported in other contexts. The EGFR ligand amphiregulin (AREG) was in particular shown to be regulated by YAP in human mammary epithelial cells or in cervical cancer cells (He et al., 2015a; Zhang et al., 2009). We did not identify Areg as deregulated in Yap CKO retinas, but we retrieved in our RNA-seq dataset four genes encoding either ligands (HB-EGF and Neuregulin1) or receptors (EGFR and ERBB4) of the pathway. Interestingly, all were reported as direct YAP target genes in human ovarian cells (He et al., 2015b), suggesting that it could be the case in Müller cells as well. Besides, our results demonstrate that EGFR signaling activity is required for YAP mitogenic effects on Müller cells. Considering that EGFR signaling is a key pathway inducing Müller glia cell-cycle re-entry (Close et al., 2005, 2006; Kari et al., 2008; Löfler et al., 2015; Todd et al., 2015; Ueki and Reh, 2013; Wan et al., 2012, 2014), such functional interaction brings YAP at the core of Müller cell reactivation mechanisms. Altogether, we propose the YAP-EGFR axis as a central player in Müller glia response to retinal damage. Interestingly, this is reminiscent of the intestinal regeneration situation, where YAP-dependent EGFR signaling has previously been reported to drive tissue repair upon injury (Gregorieff et al., 2015). Noteworthy, it was reported that EGFR-induced proliferation of Müller cells is greatly altered with age, with a proportion of proliferating cells decreasing from 86% at P8 to 9% at P12 following 6 days of explant culture (Löfler et al., 2015). YAP5SA appears much more potent as we estimated the proportion of proliferative Müller cells at about 25% at P30 following 7 days of explant culture. In addition, although EGF can stimulate Müller glia proliferation in a degenerative context, it does not have any mitogenic effect in undamaged chick or mouse retinas (Todd et al., 2015). The same holds true for the proneural transcription factor ASCL1, which promotes Müller cell reprogramming and proliferation following retinal damage, but not in the intact retina (Ueki et al., 2015). Contrasting with these data, we observed that forced YAP5SA expression in vivo is sufficient to promote Müller glia cell-cycle re-entry in a non-degenerative context. Altogether, this strongly suggests that YAP not only regulates the EGFR pathway but probably other ones, which results in robust mitogenic stimulation of Müller glia and this even in the uninjured retina.

As a whole, by identifying YAP as a powerful inducer of Müller glia proliferation, our findings open new avenues for research aimed at developing therapeutic strategies based on endogenous repair of the retina.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **Key Resources Table**
- **Contact for Reagent and Resource Sharing**
- **Experimental Model and Subject Details**
  - Mouse lines and degenerative models
  - *Xenopus* lines and regeneration models
- **Method Details**
  - Microinjection in *Xenopus* embryos
  - Mouse retinal explants
  - AAV production and retinal transduction
  - Intravitreal injection
  - Electroretinography
  - Western-blotting
  - Whole transcriptome sequencing and data analysis
  - RNA extraction and RT-qPCR
  - Histology & Immunofluorescence
  - TUNEL assay and EdU labeling
  - Imaging
- **Quantification and Statistical Analysis**
- **Data and Software Availability**

---

(C) Timeline diagram of the experimental procedure used in (D). Retinas from control and Yap CKO mice were cultured for 72 h with or without HB-EGF.

(D) Western blot analysis of Cyclin D1 expression on retinal explant extracts. α-Tubulin labeling was used to normalize the signal. n = 3 explants for the uncultured condition; n = 6 explants for all other conditions.

(E) Timeline diagram of the experimental procedure used in (F). WT, rd10, or Yap CKO; rd10 mice were intravitreally injected with PBS (control vehicle) or HB-EGF. Retinas were then harvested 2 days later.

(F) Western blot analysis of Cyclin D1 and Cyclin D3 expression on retinal extracts. α-Tubulin labeling was used to normalize the signal. n = 3–5 retinas for each condition.

(G) Timeline diagram of the experimental procedure used in (H) and (I). Retinas from WT mice were flattened, infected with AAV-YAP5SA, and cultured for 2 or 7 days in the presence of U0126 or vehicle (control).

(H) Western blot analysis of pERK and ERK expression. Shown are results from three different explants for each condition.

(I) EdU and Sox9 co-labeling in the inner nuclear layer of retinal explants. n = 6 explants for the control and 5 for the U0126-treated condition. Mann-Whitney test, “p ≤ 0.05, **p ≤ 0.01. All results are reported as mean ± SEM. ns, non-significant. Scale bar: 50 μm.
SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2019.04.045.

ACKNOWLEDGMENTS

We are grateful to S. Blackshaw, J. Wrana, and S. Meilhac for mouse lines. We are grateful to E.-K. Grellier and S. Lourdel for their help with the maintenance of mouse colonies. We would also like to thank E.-K. Grellier for performing the ERG recordings; S. Lourdel, S. Lele, K. Parain, C. Borday, and R. Langhe for their technical assistance with Xenopus experiments; and C.-J. Simon for her help with mouse intraocular injections. This work has benefited from the facilities and expertise of the high-throughput sequencing core facility of I2BC (Centre de Recherche de Gif; https://www.i2bc.paris-saclay.fr/?lang=fr). This research was supported by grants to M.P. from the FRM, AASDEV, and the DIM Région Ile de France. A.H. is an Association Retina France and ARC fellow. D.-G.-G. is a FRM fellow.

AUTHOR CONTRIBUTIONS

A.H., D.-G.-G., D.A., J.B., A.C., and J.E.R. designed and performed the experiments and analyzed the data; D.D. supervised AAV production; M.L. revised the manuscript; M.P. designed the study, analyzed the data, wrote the manuscript with the help of A.H. and D.A., and supervised the study.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES


Cell Reports 27, 1712–1725, May 7, 2019 1723


**STAR METHODS**

**KEY RESOURCES TABLE**

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse monoclonal anti-Akt</td>
<td>Sigma-Aldrich</td>
<td>Cat#P2482; RRID: AB_260913</td>
</tr>
<tr>
<td>Mouse monoclonal anti-alpha-tubulin</td>
<td>Sigma-Aldrich</td>
<td>Cat#T5168; RRID: AB_477579</td>
</tr>
<tr>
<td>Mouse monoclonal anti-alpha-tubulin</td>
<td>Sigma-Aldrich</td>
<td>Cat#T9026; RRID: AB_477593</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-arrestin</td>
<td>EMD Millipore</td>
<td>Cat#ab AB15282; RRID: AB_1163387</td>
</tr>
<tr>
<td>Mouse monoclonal anti-Brn3a</td>
<td>Santa Cruz</td>
<td>Cat#Sc-8429; RRID: AB_626765</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-calbindin D-28k</td>
<td>Swant</td>
<td>Cat#300; RRID: AB_10000347</td>
</tr>
<tr>
<td>Mouse monoclonal anti-calretinin</td>
<td>EMD Millipore</td>
<td>Cat#MAB1568; RRID: AB_94259</td>
</tr>
<tr>
<td>Rat monoclonal anti-CD68</td>
<td>Bio-Rad UK</td>
<td>Cat#MCA1957; RRID: AB_322219</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-cyclin D1</td>
<td>Abcam</td>
<td>Cat#ab 134175; RRID: AB_2750906</td>
</tr>
<tr>
<td>Mouse monoclonal anti-cyclin D3</td>
<td>Cell Signaling</td>
<td>Cat#2936; RRID: AB_2070801</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-p44/42 MAPK (ERK1/2)</td>
<td>Cell Signaling</td>
<td>Cat#9102; RRID: AB_330744</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-FLAG</td>
<td>Cell Signaling</td>
<td>Cat# F7425; RRID: AB_439867</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-GFAP</td>
<td>Dako</td>
<td>Cat#Z0334; RRID: AB_10013382</td>
</tr>
<tr>
<td>Goat polyclonal anti-GFP</td>
<td>Abcam</td>
<td>Cat#ab6673; RRID: AB_305643</td>
</tr>
<tr>
<td>Mouse monoclonal anti-glutamine synthetase</td>
<td>Abcam</td>
<td>Cat#ab 64613; RRID: AB_1140869</td>
</tr>
<tr>
<td>Peanut anti-Lectin PNA alexa 568 conjugate</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#L32458</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-phospho-Akt (Ser473)</td>
<td>Cell Signaling</td>
<td>Cat#9271; RRID: AB_329825</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)</td>
<td>Cell Signaling</td>
<td>Cat#4370; RRID: AB_2315112</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-Red Fluorescence Protein</td>
<td>Rockland</td>
<td>Cat#600-401-379; RRID: AB_2209751</td>
</tr>
<tr>
<td>Mouse monoclonal anti-Rhodopsin</td>
<td>EMD Millipore</td>
<td>Cat#MAB5316; RRID: AB_2156055</td>
</tr>
<tr>
<td>Mouse monoclonal anti-Rhodopsin</td>
<td>EMD Millipore</td>
<td>Cat#MABN15; RRID: AB_10807045</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-opsin blue</td>
<td>EMD Millipore</td>
<td>Cat#AB5407; RRID: AB_177457</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-SOX9</td>
<td>EMD Millipore</td>
<td>Cat#AB5535; RRID: AB_2239761</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-TAZ</td>
<td>Abcam</td>
<td>Cat#ab 110239</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-Vimentin</td>
<td>Santa Cruz</td>
<td>Cat#sc-7557; RRID: AB_793998</td>
</tr>
<tr>
<td>Mouse monoclonal anti-YAP</td>
<td>Abcam</td>
<td>Cat#ab 56701; RRID: AB_2219140</td>
</tr>
<tr>
<td>Rabbit monoclonal anti-YAP</td>
<td>Abcam</td>
<td>Cat#ab 52771; RRID: AB_2219141</td>
</tr>
<tr>
<td>Goat anti-mouse IgG1, Alexa 488</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A2121; RRID: AB_141514</td>
</tr>
<tr>
<td>Donkey anti-rabbit, Alexa 488</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A21206; RRID: AB_141708</td>
</tr>
<tr>
<td>Goat anti-mouse IgG1, Alexa 555</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A21127; RRID: AB_141596</td>
</tr>
<tr>
<td>Goat anti-mouse IgG2b, Alexa 555</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A211147; RRID: AB_1500897</td>
</tr>
<tr>
<td>Goat anti-mouse IgG2a, Alexa 555</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A21127; RRID: AB_141596</td>
</tr>
<tr>
<td>Donkey anti-rabbit, Alexa 555</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A31572; RRID: AB_162543</td>
</tr>
<tr>
<td>Goat anti-mouse, Alexa 488</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A11001; RRID: AB_2534069</td>
</tr>
<tr>
<td>Goat anti-mouse, Alexa 594</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A11005; RRID: AB_141372</td>
</tr>
<tr>
<td>Goat anti-rat, Alexa 594</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A11007; RRID: AB_141374</td>
</tr>
<tr>
<td>Goat anti-rabbit, Alexa 488</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A11008; RRID: AB_143165</td>
</tr>
<tr>
<td>Goat anti-rabbit, Alexa 594</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A11012; RRID: AB_141359</td>
</tr>
<tr>
<td>Goat anti-mouse IgG HRP conjugate</td>
<td>Sigma-Aldrich</td>
<td>Cat#A4146; RRID: AB_258167</td>
</tr>
<tr>
<td>Donkey anti-rabbit IgG HRP conjugate</td>
<td>GE Health</td>
<td>Cat#NA9334; RRID: AB_772206</td>
</tr>
</tbody>
</table>

(Continued on next page)
### REAGENT or RESOURCE SOURCE IDENTIFIER

#### Bacterial and Virus Strains

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAV-GFP</td>
<td>Klimczak et al., 2009</td>
<td>N/A</td>
</tr>
<tr>
<td>AAV-YAPSSA</td>
<td>This paper</td>
<td>N/A</td>
</tr>
</tbody>
</table>

#### Chemicals, Peptides, and Recombinant Proteins

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-hydroxytamoxifen</td>
<td>Sigma-Aldrich</td>
<td>Cat#H6278</td>
</tr>
<tr>
<td>Human recombinant HB-EGF</td>
<td>R&amp;D systems</td>
<td>Cat#259-HE</td>
</tr>
<tr>
<td>U0126</td>
<td>Abcam</td>
<td>Cat#ab120241</td>
</tr>
<tr>
<td>1-Methyl-1-nitrosourea (MNU)</td>
<td>Trinova Biochem</td>
<td>N/A</td>
</tr>
<tr>
<td>Metronidazole (MTZ)</td>
<td>Sigma-Aldrich</td>
<td>Cat# M-183</td>
</tr>
<tr>
<td>BrdU</td>
<td>Roche</td>
<td>Cat#10280879001</td>
</tr>
<tr>
<td>EdU</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# D1756</td>
</tr>
<tr>
<td>DAPI</td>
<td>Sigma-Aldrich</td>
<td>Cat#H4024</td>
</tr>
<tr>
<td>MS-222</td>
<td>Sigma-Aldrich</td>
<td>Cat#A5040-25G</td>
</tr>
<tr>
<td>Rompun 2% (Xylasine)</td>
<td>Bayer</td>
<td>N/A</td>
</tr>
<tr>
<td>Imalgene 500 (Ketamine)</td>
<td>MERIAL SAS</td>
<td>N/A</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>Sigma-Aldrich</td>
<td>Cat#D4092</td>
</tr>
</tbody>
</table>

#### Critical Commercial Assays

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA 6000 Nano Kit</td>
<td>Agilent Technologies</td>
<td>Cat#5067-1511</td>
</tr>
<tr>
<td>TruSeq Stranded mRNA Library Preparation Kit</td>
<td>Illumina</td>
<td>Cat#20020594</td>
</tr>
<tr>
<td>RNeasy mini kit</td>
<td>QIAGEN</td>
<td>Cat#74104</td>
</tr>
<tr>
<td>NucleoSpin RNA Plus kit</td>
<td>Macherey Nagel</td>
<td>Cat#740984.50</td>
</tr>
<tr>
<td>mMessage mMachine kit</td>
<td>Life Technologies</td>
<td>Cat#AM1340</td>
</tr>
<tr>
<td>DC Protein Assay</td>
<td>Bio-Rad</td>
<td>Cat#500-0116</td>
</tr>
<tr>
<td>SuperScript II Reverse Transcriptase kit</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#18064-071</td>
</tr>
<tr>
<td>IsoFast EvaGreen supermix</td>
<td>Bio-Rad</td>
<td>Cat#172-5204</td>
</tr>
<tr>
<td>SYBR select master mix</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#4472908</td>
</tr>
<tr>
<td>DeadEnd Fluorometric TUNEL System</td>
<td>Promega</td>
<td>Cat#G3250</td>
</tr>
<tr>
<td>Click-IT Plus EdU Alexa Fluor 555 Imaging Kit</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#C10338</td>
</tr>
<tr>
<td>Click-IT Plus EdU Alexa Fluor 647 Imaging Kit</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#C10640</td>
</tr>
<tr>
<td>Click-IT Plus EdU Alexa Fluor 488 Imaging Kit</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#C10337</td>
</tr>
</tbody>
</table>

#### Deposited Data

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNaseq dataset</td>
<td>This paper</td>
<td>GEO: GSE121858</td>
</tr>
<tr>
<td>RNaseq dataset</td>
<td>Hamon et al., 2017</td>
<td>GEO: GSE94534</td>
</tr>
</tbody>
</table>

#### Experimental Models: Organisms/Strains

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse: C57Bl6/J</td>
<td>Jackson Laboratory</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse: B6.CXB1-Pde6b/Pde6b/J</td>
<td>Bo Chang; Chang et al., 2007</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse: Yapfl/fl</td>
<td>Jeff Wrana; Reginensi et al., 2013</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse: Rax-CreERT²</td>
<td>Seth Blackshaw; Pak et al., 2014</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse: Rax-CreERT², R26-CAG-lox-stop-lox-TdTom (Ai9)</td>
<td>Seth Blackshaw; Pak et al., 2014</td>
<td>N/A</td>
</tr>
<tr>
<td>Xenopus laevis: WT</td>
<td>Centre de Ressources Biologiques Xénoposes (CRB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Xenopus laevis: Tg(hsp70:dnYap-GFP, cryga:tdTomato)</td>
<td>UK Xenopus resource center; Hayashi et al., 2014b</td>
<td>N/A</td>
</tr>
<tr>
<td>Xenopus laevis: Tg(Rho:GFP-NTR)</td>
<td>Langhe et al., 2017</td>
<td>N/A</td>
</tr>
</tbody>
</table>

#### Oligonucleotides

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primers for genotyping, see Table S2</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Primers for RT-qPCR, see Table S2</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

(Continued on next page)
CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Muriel Perron (muriel.perron@u-psud.fr).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

All animal experiments have been carried out in accordance with the European Community Council Directive of 22 September 2010 (2010/63/EEC). All animal cares and experimentations were conducted in accordance with institutional guidelines, under the institutional license D 91-272-105 for mice and the institutional license C 91-471-102 for *Xenopus*. The study protocols were approved by the institutional animal care committee CEEA n°59 and received an authorization by the “Ministère de l’Education Nationale, de l’Enseignement Supérieur et de la Recherche” under the reference APAFIS#1018-2016072611404304v1 for mice experiments and APAFIS#998-2015062510022908v2 for *Xenopus* experiments.

**Mouse lines and degenerative models**

Mice were kept at 21°C, under a 12-hour light/12-hour dark cycle, with food and water supplied *ad libitum*. Yap^flox/flox^ mice were obtained from Jeff Wrana’s lab (Reginensi et al., 2013) and crossed with heterozygous *Rax-CreERT^2^* knock-in mice or double heterozygous *Rax-CreER^2^, R26-CAG-lox-stop-lox-TdTom (Ai9)* mice from Seth Blackshaw’s lab (Pak et al., 2014) to generate Yap^flox/flox^;Rax-CreERT^2^ (Yap CKO) and Yap^flox/flox^;Rax-CreER^2^;Ai9 (Yap CKO; Ai9) mice. Primer sequences used for genotyping tail snip genomic DNA are provided in Table S2. Cre activity was induced through a single intraperitoneal injection of 4-hydroxytamoxifen (4-OHT; 1 mg) at P10, as previously described (Pak et al., 2014). To generate the Yap^flox/flox^;Rax-CreER^2^;rd10 line (Yap CKO; rd10), Yap^flox/flox^;Rax-CreER^2^ mice were crossed with homozygous rd10 mice (Pde6b^rd10^; a model of retinitis pigmentosa, with a mutation in *phosphodiesterase-6b* (*Pde6b*) gene (Chang et al., 2007); The Jackson Laboratory, Bar Harbor, ME, USA). Chemically-induced retinal degeneration was performed through a single intraperitoneal injection of 1-Methyl-1-nitrosourea (MNU, Trinova Biochem) at 60 mg/kg body weight, as previously described (Hamon et al., 2017). All experiments involving adult mice were performed with male or female mice that were 3 to 8 weeks. No difference between sexes was observed in any retinal phenotype.

**Xenopus lines and regeneration models**

*Xenopus laevis* tadpoles were obtained by conventional procedures of *in vitro* or natural fertilization, staged according to Nieuwkoop and Faber method (Nieuwkoop and Faber, 1994) and raised at 18-20°C. Heat-shock-inducible dominant-negative YAP transgenic line *Tg(*hsp70:dnYap-GFP, cryga:tdTomato)* (*Hayashi et al., 2014b*) (*Tg(dnYAP)* was obtained from the UK Xenopus resource center (EXRC). Heat-shock-mediated dnYAP expression was induced by shifting the animals from 18-20°C to 34°C for 30 min as previously described (Hayashi et al., 2014b). The transgenic *Xenopus* line *Tg(Rho:GFP-NTR)* (*Tg(NTR)* used for conditional rod ablation was
generated in the lab and previously described (Langhe et al., 2017). Photoreceptor degeneration was induced by bathing the froglets in a 10 mM MTZ (Sigma-Aldrich) solution for 1 week (Langhe et al., 2017). Retinal mechanical injury was performed as previously described (Langhe et al., 2017), by poking the retina once under a stereomicroscope with a needle (Austerlitz Insect Pins, 0.2 mm), without damaging the cornea or the lens. For cell proliferation assays, *Xenopus* tadpoles (i.e., pre-metamorphic individuals) or froglets (i.e., post-metamorphic individuals) were immersed in a solution containing 1 mM BrdU (5′-bromo-2′-deoxyuridine, Roche) for 3 days or 1 week, as indicated. The solution was renewed every other day.

**METHOD DETAILS**

**Microinjection in Xenopus embryos**

The *Xenopus* construct YapS98A, encoding a constitutively active YAP protein (Ser-98 residue substituted with an alanine), was provided by S Gee and S Moody (Gee et al., 2011) and subcloned into pCS2*+* (pCS2-YapS98A) (Cabochette et al., 2015). A glucocorticoid-inducible FLAG-tagged version of YAP5SA (YAP5SA-GR) was then generated by subcloning in frame the YapS98A coding sequence from pCS2-YapS98A plasmid into the EcoRI and XhoI sites of pCS2-FLAG-GR (Talikka et al., 2002) (pCS2-FLAG-YapS98A-GR). Following *in vitro* transcription (mMessage mMachine kit, Life Technologies), 200 pg of mRNA were injected at the one-cell stage. LacZ mRNAs were injected as controls. Activity of the chimeric YAP5SA-GR protein was induced by addition of 4 mg/ml dexamethasone (dex, Sigma-Aldrich) into the embryo rearing medium.

**Mouse retinal explants**

Retinas from enucleated P30 eyes were dissected in Hanks’ Balanced Salt solution (GIBCO) by removing the anterior segment, vitreous body, sclera and RPE. They were then flat-mounted onto a microporous membrane (13 mm in diameter; Merk Millipore) in a twelve-well culture plate, with the ganglion cell layer facing upward. Each well contained 700 μl of culture medium, consisting in DMEM-Glutamax (GIBCO) supplemented with 1% FBS, 0.6% D-Glucose, 0.2% NaHCO3, 5mM HEPES, 1% B27, 1% N2, 1X Penicillin-Streptomycin. Culture medium containing 100 ng/mL human recombinant HB-EGF (R&D systems), 10 μM of U0126 (Abcam) or vehicle was added from the beginning of the explant culture. Explants were maintained at 37° C in a humidified incubator with 5% CO2. Half of the culture medium was changed daily. For proliferation assays, 20 mM EdU was applied 7 or 12 days before fixation.

**AAV production and retinal transduction**

Human YAP5SA cDNA was amplified by PCR from pCMV-flag-YAP2-5SA plasmid (a gift from Kunliang Guan, Addgene plasmid#27371; http://addgene.org/27371; RRID:Addgene_27371) and subcloned into an AAV transfer plasmid, where the expression is driven by the minimal cytomegalovirus (CMV) promoter (Klimczak et al., 2009). AAV vectors were produced as already described using the co-transfection method and purified by iodixanol gradient ultracentrifugation (Choi et al., 2015). AAV vector stocks were tittered by qPCR using SYBR Green (Thermo Fisher Scientific) (Aurnhammer et al., 2012). The previously engineered AAV-GFP (Klimczak et al., 2009) was used as a control. 1011 vg of AAV-GFP or AAV-YAP5SA were applied on mouse retinal explants for viral transduction. Infected explants were cultured for 7 or 12 days as indicated before further western blot analysis or EdU labeling.

**Intravitreal injection**

Mice were first anesthetized through intraperitoneal injection of ketamine (90 mg/kg, Merial) and xylazine (8 mg/kg, Bayer). They were then topically administered tropicamide (0.5%) and phenylephrine (2.5%) for pupillary dilation. While applying gentle pressure around the eye socket to extrude the eye, a 30-gauge needle was passed through the sclera just behind the limbus, into the vitreous cavity. Injection of 2 μl of AAV (1013 vg/ml) or 1 μl of 100 μg/mL HB-EGF (R&D systems) or 1 μl of 1 μg/ml EdU (Thermo Fisher Scientific) was made with direct observation of the needle in the center of the vitreous cavity.

**Electroretinography**

Electroretinograms (ERGs) were recorded using a Micron IV focal ERG system (Phoenix Research Labs). Mice were dark-adapted overnight, prepared for recording in darkness under dim-red illumination and finally anesthetized as described above. Flash ERG recordings were obtained from one eye. ERG responses were recorded using increasing light intensities ranging from −1.7 to 2.2 log cd·s/m2 under dark-adapted conditions, and from −0.5 to 2.8 log cd·s/m2 under a background light that saturates rod function. The interval between flashes varied from 0.7 s at the lowest stimulus strength to 15 s at the highest one. Five to thirty responses were averaged depending on flash intensity. Analysis of a-wave and b-wave amplitudes was performed using LabScribeERG software. The a-wave amplitude was measured from the baseline to the negative peak and the b-wave was measured from the baseline to the maximum positive peak.

**Western-blotting**

Each protein extract was obtained from a single retina, quickly isolated and frozen at −80° C. Retinas were then lysed in P300 buffer (20 mM Na2HPO4; 250 mM NaCl; 30 mM NaPPI; 0.1% Nonidet P-40; 5 mM EDTA; 5mM DTT) supplemented with protease inhibitor...
cocktail (Sigma-Aldrich). Lysate concentration was determined using the Lowry protein assay kit (DC Protein Assay; Bio-Rad) and 20 μg/lane of each sample were loaded for western-blot analysis. Between 3 and 6 individuals were tested per condition. Primary/secondary antibodies and their corresponding working dilutions are listed in Table S3. Protein detection was performed using an enhanced chemiluminescence kit (Bio-Rad). Each sample was probed once with anti-α-tubulin antibody for normalization. Quantification was done using Fiji software (National Institutes of Health) (Schindelin et al., 2012).

Whole transcriptome sequencing and data analysis
Whole transcriptome analysis was performed on three independent biological replicates from MNU-injected control and MNU-injected Yap CKO retinas at P60 and compared to WT dataset previously published (Hamon et al., 2017) (GEO accession number GSE94534). After harvesting, both retinas for each animal were immediately frozen. RNA was extracted using Nucleospin RNA Plus kit (Macherey-Nagel). RNA quality and quantity were evaluated using a BioAnalyzer 2100 with RNA 6000 Nano Kit (Agilent Technologies). Stranded RNA-Seq libraries were constructed from 100 ng high-quality total RNA (RIN > 8) using the TrueSeq Stranded mRNA Library Preparation Kit (Illumina). Paired-end sequencing of 40 bases length was performed on a NextSeq 500 system (Illumina). Pass-filtered reads were mapped using HISAT2 2.1.0 and aligned to mouse reference genome GRCm38 (Kim et al., 2015; Pertea et al., 2016). Count table of the gene features was obtained using FeatureCounts (Liao et al., 2014). Normalization, differential expression analysis and FPKM (fragments per kilobase of exon per million fragments mapped) values were computed using EdgeR (Robinson et al., 2010). An FPKM filtering cutoff of 1 in at least one of the 6 samples was applied. A differential expression analysis and FPKM values were computed of Genes and Genome (KEGG). Data visualization was done using GOplot R package (Walter et al., 2015).

RNA extraction and RT-qPCR
Total RNA was extracted from mouse neural retina or whole Xenopus tadpoles using RNeasy mini kit (QIAGEN) or NucleoSpin RNA Plus kit (Macherey Nagel), respectively. RNA concentration was assessed using the NanoDrop 2000c UV-Vis spectrophotometer (Thermo Fisher Scientific). For each RT-qPCR reaction, 1.5 ng of cDNA was used in triplicates in the presence of EvaGreen (Bio-Rad) on a CFX96 Real-Time PCR Detection System (Bio-Rad). Differential expression analysis was performed using the ΔΔCt method using the geometric mean of Rps26, Srp72 and Tbp as endogenous controls (Vandesompele et al., 2002) for mouse genes, and of Rpil8 and Odc1 as endogenous controls for Xenopus genes. Relative expression of each gene in each sample was calculated using the mean of the controls as the reference (1 a.u.). Primers are listed in Table S2. RT-qPCR experiments were performed on at least 5 mice or 3 tadpoles per condition, allowing for statistical analysis.

Histology & Immunofluorescence
Pre- and post- metamorphic Xenopus individuals were anesthetized in 0.4% MS222 (Sigma-Aldrich) and then fixed in 1X PBS, 4% paraformaldehyde, overnight at 4°C. For mice, the eyes of sacrificed animals were rapidly enucleated and dissected in Hanks’ Balanced Salt solution (GIBCO) to obtain posterior segment eye-cups, which were then fixed in 1X PBS, 4% paraformaldehyde for 1 hr at 4°C. Fixed samples were dehydrated, embedded in paraffin and sectioned (7μm) with a Microm HM 340E microtome (Thermo Scientific). Fixed retinal explants were sectioned (7μm) with a Microm HM550 cryostat (Thermo Scientific), following embedding in 1X PBS, 7.5% gelatin, 10% sucrose. Immunostaining on retinal sections or whole explants was performed using standard procedures with the following specificities: (i) An antigen unmasking treatment was done in boiling heat-mediated antigen retrieval buffer (10 mM sodium citrate, pH 6.0) for 20 min; (ii) For Xenopus sections, this was followed by a 45 min treatment in 2N HCl at room temperature; (iii) Incubation timing was increased at all steps for immunolabelling on retinal explants. Primary/secondary antibodies and their corresponding working dilutions are listed in Table S3. Nuclei were counterstained with 1μg/ml DAPI (Thermo Fisher Scientific) or Hoechst (Sigma-Aldrich). H&E staining was performed using standard procedure.

TUNEL assay and EdU labeling
Detection of apoptotic cells was conducted on retinal sections using DeadEnd Fluorometric TUNEL System (Promega) according to the manufacturer’s instructions. EdU incorporation was detected using the Click-IT EdU Imaging Kit (Thermo Fisher Scientific) following the manufacturer’s recommendations. Coverslips were mounted using Fluoroseave Reagent (Millipore, USA).

Imaging
Fluorescence and brightfield images were acquired using an ApoTome-equipped Axiolmager.M2 microscope or a Zeiss LSM710 confocal microscope. Whole retinal explants were imaged using an AxioZoom.v16 (Zeiss). Image mosaics of whole explants or flat mounted retinas were acquired and combined by the stitching processing method using ZEN Tiles module (Zeiss). Images were processed using Zen (Zeiss), Fiji (National Institutes of Health) and Photoshop CS4 (Adobe) softwares. The same magnification, laser intensity, gain and offset settings were used across animals for any given marker.
QUANTIFICATION AND STATISTICAL ANALYSIS

Quantifications in Xenopus: all labeled cells were counted manually. 3 to 10 sections were analyzed for each retina, and an average number was calculated from at least 5 retinas. BrdU-positive cells were counted within the Xenopus neural retina (after exclusion of the ciliary marginal zone). The size of dissected Xenopus eyes was estimated by measuring the surface of the corresponding pictures using Photoshop CS4 (Adobe) software. Quantifications in mouse: mean number of labeled cells in mouse retinal explants were calculated from 3 different fields of \(10^4\) mm\(^2\) per retina and using 3 explants per condition (for quantifications on whole explants) or from one field of \(10^4\) mm\(^2\) per section and using minimum 3 different retinas per condition (for quantifications on explant sections). SOX9-positive mouse Müller cells in Figure 1 were quantified by considering one entire retinal section from 3 different mice for each condition. Statistical analysis was performed with GraphPad Prism 5.01 (GraphPad Software, La Jolla California USA) using the non-parametric Mann-Whitney test in all experiments, except ERG, for which we applied a two-way ANOVA test. p value \(\leq 0.05\) was considered significant. All results are reported as mean ± SEM.

DATA AND SOFTWARE AVAILABILITY

RNaseq dataset from MNU-injected control and MNU-injected Yap CKO retinas has been deposited at the Gene Expression Omnibus under the ID code GEO: GSE121858.